

IB 230035

Description

IB 230035 cells were isolated from the brain tissue of a patient with Glioblastoma Multiforme. These patient derived cells (PDC) can be used in cancer, immuno-oncology, and toxicology research.

Organism:	<i>Homo sapien</i> , human	Disease Type:	Glioblastoma Multiforme
Patient Age:	Unknown	Cancer Cell Type:	Glial Cells
Patient Sex:	Unknown	Cell Morphology:	Adherent (epithelial-like)
Tissue of Origin:	Brain	Applications:	2D and 3D cell culture

Growth Characteristics and Images

Optimal Seeding Density:	8 x 10 ⁶ cells/cm ²
Doubling Rate:	~ 28 hours
Expected Viability:	>95%
Average Diameter:	16.4 μm




Figure 1: Representative brightfield microscope images of IB 230035 taken at 10X magnification.

Model Response to Standard of Care Chemotherapeutics

Table 4: IC₅₀ values of 9 standard of care chemotherapeutic agents for IB 230035 over 3 incubation periods. Each IC₅₀ values represents an average of 2 biological replicates

COMPOUND	IC ₅₀ (DAY 3) (M)	IC ₅₀ (DAY 5) (M)	IC ₅₀ (DAY 7) (M)
CARMUSTINE	5.139E-01	9.239E-05	2.611E-05
TEMOZOLOMIDE	5.009E+06		3.498E-05
PROCARBAZINE-HCL	<1.00E-03		2.014E-04
5-FLUOROURACIL			2.164E-04
TAMOXIFEN	3.437E-06		4.283E-06
CISPLATIN	3.193E-06		1.429E-06
LETROZOLE	2.546E-05		9.961E-05
GEMCITABINE			6.273E-09
PACLITAXEL	4.158E-09		1.958E-09

Numbers in grey are indication only due to incomplete curves

Intended Use

Registered in England and Wales
Company Number: 14589984 | VAT Number: GB 433 3053 332
UK Registered Office Address: Stonebridge House, Chelmsford Road, Hatfield Heath, England, CM22 7BD

This product is intended for laboratory research use only. It is not intended for therapeutic use, consumption, or diagnostic testing in humans or animals.

Revision

Version 1: Initial Preparation

This information on this document was last updated on 2023-12-21

Contact information

Inaphaea Biolabs Ltd
Medicity, D6 Thane Road,
Nottingham,
NG90 6BH.
Contact number:
Email: info@inaphaea.com